Peer-reviewed publication
Serum proteomic profiling and chemotherapy response in advanced NSCLC
A peer-reviewed cancer proteomics study exploring how serum protein patterns may help distinguish chemotherapy responders from non-responders in advanced non-small cell lung cancer.
This publication focused on advanced non-small cell lung cancer patients receiving first-line platinum-based carboplatin/paclitaxel chemotherapy. The research compared serum proteomic profiles between responders and non-responders to explore molecular patterns associated with treatment response.
As part of the research team, I contributed to a study that combined label-free LC-MS/MS serum proteomic profiling, bioinformatics analysis, and pathway interpretation to identify proteins and biological processes linked to chemotherapy response.
The study reported differentially expressed serum proteins and highlighted IGHG3 and A1AG1 as potential predictors of chemotherapeutic response. The findings also pointed to biological pathways such as complement and coagulation cascades as relevant signals in the responder versus non-responder comparison.
For my profile, this work represents an early peer-reviewed contribution in cancer proteomics, connecting biomedical sample analysis, computational interpretation, and clinically relevant biomarker discovery.
